Increased soluble 4-1BB ligand (4-1BBL) levels in peripheral blood of patients with multiple sclerosis

Scandinavian Journal of Immunology

Volumn 64, Issue 4, 2006, Pages 412-419

  Liu, G Z ^a,b   Gomes, A C ^b   Putheti, P ^b   Karrenbauer, V ^b   Kostulas, K ^b   Press, R ^b   Hillert, J ^b   Hjelmstrom P ^b   Gao, X G ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 LIGAND; CD14 ANTIGEN; MYELIN BASIC PROTEIN; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BLOOD; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LYMPHOCYTE PROLIFERATION; MALE; MONOCYTE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

4-1BB LIGAND; ADULT; ANTIGENS, CD; ANTIGENS, CD137; ANTIGENS, CD14; CELLS, CULTURED; FEMALE; HUMANS; LIGANDS; MALE; MONOCYTES; MULTIPLE SCLEROSIS; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER; SIGNAL TRANSDUCTION; SOLUBILITY; TUMOR NECROSIS FACTORS;

EID: 33748799128     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2006.01796.x     Document Type: Article

References (58)

1. Hafler DA, Slavik JM, Anderson DE, O'Connor KC, Jager PD, Baecher-Allan C. Multiple sclerosis. Immunol Rev 2005;204:208-31.
2. Hemmer B, Cepok S, Nessler S, Sommer N. Pathogenesis of multiple sclerosis: an update on immunology. Curr Opin Neurol 2002;15:227-31.
3. Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 2002;20:29-53.
4. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001;19:225-52.
5. Croft M. Costimulation of T cells by OX40, 4-1BB, and CD27, cytokine. Growth Factor Rev 2003;14:265-73.
6. + T cells. Trends Immunol 2002;23:378-80.
7. Pollok KE, Kim YJ, Zhou Z et al. Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol 1993;150:771-81.
8. Schwarz H, Valbracht J, Tuckwell J, von Kempis J, Lotz M. ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages. Blood 1995;85:1043-52.
9. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 1998;190:167-72.
10. Pauly S, Broll K, Wittmann M, Giegerich G, Schwarz H. CD137 is expressed by follicular dendritic cells and costimulates B lymphocyte activation in germinal centers. J Leukoc Biol 2002;72:35-42.
11. Heinisch IV, Bizer C, Volgger W, Simon HU. Functional CD137 receptors are expressed by eosinophils from patients with IgE-mediated allergic responses but not by eosinophils from patients with non-IgE-mediated eosinophilic disorders. J Allergy Clin Immunol 2001;108:21-8.
12. Kienzle G, von Kempis J. CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes. Int Immunol 2000;12:73-82.
13. Heinisch IV, Daigle I, Knopfli B, Simon HU. CD137 activation abrogates granulocyte-macrophage colony-stimulating factor-mediated anti-apoptosis in neutrophils. Eur J Immunol 2000;30:3441-6.
14. Gavin MA, Clarke SR, Negrou E, Gallegos A, Rudensky A. Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo. Nat Immunol 2002;3:33-41.
15. McHugh RS, Whitters MJ, Piccirillo CA et al. CD4 (+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002;16:311-23.
16. Goodwin RG, Din WS, Davis-Smith T et al. Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur J Immunol 1993;23:2631-41.
17. Pollok KE, Kim YJ, Hurtado J, Zhou Z, Kim KK, Kwon BS. 4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-mu-primed splenic B cells. Eur J Immunol 1994;24:367-74.
18. DeBenedette MA, Chu NR, Pollok KE et al. Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphomas by camp. J Exp Med 1995;181:985-92.
19. Myers LM, Vella AT. Interfacing T-cell effector and regulatory function through CD137 (4-1BB) co-stimulation. Trends Immunol 2005;26:440-6.
20. DeBenedette MA, Shahinian A, Mak TW, Watts TH. Costimulation of CD28- T lymphocytes by 4-1BB ligand. J Immunol 1997;58:551-9.
21. - T cells. J Immunol 1997;158:3081-9.
22. Saoulli K, Lee SY, Cannons JL et al. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J Exp Med 1998;187:1849-62.
23. DeBenedette MA, Wen T, Bachmann MF et al. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus. J Immunol 1999;163:4833-41.
24. Guinn BA, DeBenedette MA, Watts TH, Berinstein NL. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. J Immunol 1999;162:5003-10.
25. Tan JT, Whitmire JK, Ahmed R, Pearson TC, Larsen CP. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses. J Immunol 1999;163:4859-68.
26. Wiethe C, Dittmar K, Doan T, Lindenmaier W, Tindle R. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen. J Immunol 2003;170:2912-22.
27. Bukczynski J, Wen T, Watts TH. Costimulation of human CD28-T cells by 4-1BB ligand. Eur J Immunol 2003;33:446-54.
28. Seko Y, Takahashi N, Oshima H et al. Expression of tumour necrosis factor (TNF) ligand superfamily co-stimulatory molecules CD30L, CD27L, OX40L, and 4-1BBL in murine hearts with acute myocarditis caused by Coxsackievirus B3. J Pathol 2001;195:593-603.
29. Seo SK, Park HY, Choi JH et al. Blocking 4-1BB/4-1BB ligand interactions prevents herpetic stromal keratitis. J Immunol 2003;171:576-83.
30. Seko Y, Ishiyama S, Nishikawa T et al. Expression of tumor necrosis factor ligand superfamily costimulatory molecules CD27L, CD30L, OX40L and 4-1BBL in the heart of patients with acute myocarditis and dilated cardiomyopathy. Cardiovasc Pathol 2002;11:166-70.
31. Yndestad A, Kristian Damas J, Geir Eiken H et al. Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. Cardiovasc Res 2002;54:175-82.
32. Bossowski A, Stasiak-Barmuta A, Urban M, Bossowska A. Analysis of costimulatory molecules OX40/4-1BB (CD134/CD137) detection on chosen mononuclear cells in children and adolescents with Graves' disease during methimazole therapy. J Pediatr Endocrinol Metab 2005;18:1365-72.
33. Michel J, Langstein J, Hofstadter F, Schwarz H. A soluble form of CD137 (ILA/4-1BB), a member of the TNF receptor family, is released by activated lymphocytes and is detectable in sera of patients with rheumatoid arthritis. Eur J Immunol 1998;28:290-5.
34. Sharief MK. Heightened intrathecal release of soluble CD137 in patients with multiple sclerosis. Eur J Neurol 2002;9:49-54.
35. Salih HR, Schmetzer HM, Burke C et al. Soluble CD137 (4-1BB) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies. J Immunol 2001;167:4059-66.
36. Jung HW, Choi SW, Choi JI, Kwon BS. Serum concentrations of soluble 4-1BB and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis. Exp Mol Med 2004;36:13-22.
37. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:444-52.
38. Phillips TA, Ni J, Hunt JS. Death-inducing tumour necrosis factor (TNF) superfamily ligands and receptors are transcribed in human placentae, cytotrophoblasts, placental macrophages and placental cell lines. Placenta 2001;22:663-72.
39. Gomes AC, Jönsson G, Mjörnheim S, Olsson T, Hillert J, Grandien A. Upregulation of the apoptosis regulators cFLIP, CD95 and CD95 ligand in peripheral blood mononuclear cells in relapsing-remitting multiple sclerosis. J Neuroimmunol 2003;135:126-34.
40. Prat A, Antel J. Pathogenesis of multiple sclerosis. Curr Opin Neurol 2005;18:225-30.
41. Racke MK, Ratts RB, Arredondo L, Perrin PJ, Lovett-Racke A. The role of costimulation in autoimmune demyelination. J Neuroimmunol 2000;107:205-15.
42. Stuart RW, Racke MK. Targeting T cell costimulation in autoimmune disease. Expert Opin Ther Targets 2002;6:275-89.
43. Sun Y, Lin X, Chen HM et al. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J Immunol 2002;168:1457-65.
44. Stasiolek M, Bayas A, Kruse N et al. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain 2006;129:1293-305.
45. Bielekova B, Goodwin B, Richert N et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000;6:1167-75.
46. Bieganowska KD, Ausubel LJ, Modabber Y, Slovik E, Messersmith W, Hafler DA. Direct ex vivo analysis of activated, Fas-sensitive autoreactive T cells in human autoimmune disease. J Exp Med 1997;185:1585-94.
47. Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner HL, Hafler DA. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med 1994;179:973-84.
48. Wucherpfennig KW, Zhang J, Witek C et al. Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. J Immunol 1994;152:5581-92.
49. + T cells in multiple sclerosis. J Immunol 1999;162:1811-7.
50. Allegretta M, Nicklas JA, Sriram S, Albertini RJ. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 1990;247:718-21.
51. Allegretta M, Albertini RJ, Howell MD et al. Homologies between T cell receptor junctional sequences unique to multiple sclerosis and T cells mediating experimental allergic encephalomyelitis. J Clin Invest 1994;94:105-9.
52. Lovett-Racke AE, Trotter JL, Lauber J, Perrin PJ, June CH, Racke MK. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. J Clin Invest 1998;101:725-30.
53. Zhang JW, Medaer R, Chin Y, van den Berg-Loonen E, Raus JCM. Myelin basic protein-specific T lymphocytes in multiple sclerosis and controls: precursor frequency, fine specificity, and cytotoxicity. Ann Neurol 1992;32:330-9.
54. Avolio C, Ruggieri M, Giuliani F et al. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol 2003;136:46-53.
55. Galboiz Y, Shapiro S, Lahat N, Rawashdeh H, Miller A. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann Neurol 2001;50:443-51.
56. Trojano M, Avolio C, Liuzzi GM et al. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 1999;53:1402-8.
57. Waubant E, Goodkin DE, Gee L et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 1999;53:1397-401.
58. Kashii Y, Giorda R, Herberman RB, Whiteside TL, Vujanovic NL. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J Immunol 1999;163:5358-66.